Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2.
Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM. · 2014
Read Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2. by Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4049806.txt.
Introduction
Jason D. Ulrich and nine colleagues test whether losing one copy of the gene TREM2 worsens amyloid disease in mice, in Molecular Neurodegeneration in 2014. Variants in TREM2 sharply raise the odds of Alzheimer's disease. The gene works in microglia, the brain's immune cells, which gather around amyloid plaques.
The team crossed TREM2-variant mice with a strain that builds plaques early. Plaque load at three and seven months was unchanged by the missing copy. The microglial response was not. At three months, mice with one copy had fewer and smaller plaque-hugging microglia. Signs of inflammation trended lower too, though not past the bar for firm claims. By seven months the gap had closed. The results suggest TREM2 shapes how microglia answer plaques, not how much amyloid forms.
Catalog record
| CREATOR | Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2 By Jason D Ulrich, Mary Beth Finn, Yaming Wang, Alice Shen, Thomas E Mahan, Hong Jiang, Floy R Stewart, Laura Piccio, Marco Colonna, David M Holtzman Published in: Molecular Neurodegeneration DOI: 10.1186/1750-1326-9-20 ABSTRACT Abstract Background Recent genome-wide association studies linked variants in TREM2 to a strong increase in the odds of developing Alzheimer’s disease. The mechanism by which TREM2 influences the susceptibility to Alzheimer’s disease is currently unknown. TREM2 is expressed by microglia and is thought to regulate phagocytic and inflammatory microglial responses to brain pathology. Given that a single allele of variant TREM2, likely resulting in a loss of function, conferred an increased risk of developing Alzheimer’s disease, we tested whether loss of one functional trem2 allele would affect Aβ plaque deposition or the microglial response to Aβ pathology in APPPS1-21 mice. Results There was no significant difference in Aβ deposition in 3-month old or 7-month old APPPS1-21 mice expressing one or two copies of trem2. However, 3-month old mice with one copy of trem2 exhibited a marked decrease in the number and size of plaque-associated microglia. While there were no statistically significant differences in cytokine levels or markers of microglial activation in 3- or 7-month old animals, there were trends towards decreased expression of NOS2, C1qa, and IL1a in 3-month old TREM2+/− vs. TREM2+/+ mice. Conclusions Loss of a single copy of trem2 had no effect on Aβ pathology, but altered the morphological phenotype of plaque-associated microglia. These data suggest that TREM2 is important for the microglial response to Aβ deposition but that a 50% decrease inTREM2 expression does not affect Aβ plaque burden. Keywords: Alzheimer’s disease, TREM2, Microglia, Amyloid β BACKGROUND One of the hallmarks of Alzheimer’s disease (AD) is the extracellular deposition of amyloid-β (Aβ) peptide in the brain parenchyma as amyloid plaques. Autosomal dominant Alzheimer’s disease (ADAD) is an early-onset form of AD which is caused by rare mutations in amyloid β (A4) precursor protein (APP), presenilin-1 (PSEN1), or presenilin-2 (PSEN2) that alter Aβ production [1]. Genetic variants also influence the risk of developing the more common late onset form of AD (LOAD). To date the two strongest identified LOAD genetic risk factors are the well-studied apolipoprotein ϵ4 (APOE4) allele and several recently identified variants in the triggering receptor expressed on myeloid cells-2 (TREM2) gene [2-4]. While these variants are not common, since TREM2 variants strongly increase the risk of developing AD, understanding how TREM2 dysfunction affects AD pathology could yield novel therapeutic strategies. TREM2 encodes a transmembrane protein possessing an extracellular IgG-like ligand binding domain and an intracellular region that associates with the immunoreceptor tyrosine based activating motif (ITAM)-containing signaling adaptor protein DAP12 [5]. Individuals that are homozygous for loss of function mutations in either TREM2 or TYROBP (DAP12) suffer from polycystic lipomembranous osteodysplasia and sclerosing leukoencephalopathy (PLOSL) which is characterized by early onset dementia and cystic bone lesions [6]. Within the brain, TREM2 is expressed by microglia and appears to regulate microglial-mediated phagocytic clearance of cellular debris and the inflammatory response of microglia to pathology, however the endogenous ligand(s) for TREM2 are unknown [7-10]. TREM2 expression is increased in plaque-associated microglia in APP23 and TgCRND8 mice suggesting that TREM2 is involved in the microglial response to Aβ plaque deposition [3,11,12]. The role of microglia in AD is complex and incompletely understood. Microglia rapidly migrate to Aβ plaque deposits and acquire an amoeboid “activated” morphology [13,14]. Pro-inflammatory M1-like microglial activation is generally considered neurotoxic, while pro-phagocytic M2-like activation can lead to microglial clearance of Aβ in murine AD models [15]. Since TREM2 is implicated in regulating the phagocytic and inflammatory function of macrophages, TREM2 dysfunction could conceivably increase Aβ plaque burden through decreased phagocytic clearance of Aβ and/or promote a neurotoxic, inflammatory microglial phenotype in response to Aβ deposition. In this study we tested whether loss of a single trem2 allele affected Aβ plaque burden in APPPS1-21 mice[16]. To facilitate analysis of microglia we took advantage of the CX3CR1-GFP mice which in the CNS express GFP specifically within microglia [17]. Although we did not observe a significant difference in Aβ plaque deposition between TREM2+/+ and TREM2+/− mice, there was a substantial decrease in plaque-associated microglia in TREM2+/− mice compared to TREM2+/+ mice. These data suggest that TREM2 function may affect the microglial response to Aβ pathology. RESULTS TREM2 hemizygosity does not affect Aβ deposition in 3-month old APPPS1-21 mice Individuals that are heterozygous for TREM2 variants predicted to result in a decrease or loss of TREM2 function in the affected allele, have increased odds of developing AD [3,4]. TREM2 expression in microglia is associated with phagocytic clearance of extracellular debris, such as apoptotic neurons, raising the possibility that TREM2 could regulate microglial mediated clearance of extracellular Aβ, and ultimately amyloid plaque deposition [8]. We compared the amount of cortical Aβ deposition in the early stages of plaque formation using 3-month old APPPS1-21 mice expressing two copies (TREM2+/+, CX3CR1+/GFP, APPPS1-21, referred to as TREM2 WT) (Figure 1A,C) or one copy of TREM2 (TREM2+/−, CX3CR1+/GFP, APPPS1-21, referred to as TREM2 Het) (Figure 1B,D). We observed significantly more Aβ deposition in female mice compared to male mice for both TREM2 WT and TREM2 Het mice; however, we did not detect a significant effect of TREM2 copy number on Aβ deposition (Figure 1E). We further examined whether TREM2 affected amyloid deposition by staining brain sections with X-34, a dye that binds to fibrillar Aβ [18]. Again, we observed approximately double the amount of amyloid staining in female mice compared to male mice, but no significant difference between TREM2 WT and TREM2 Het mice (Figure 1F). We also biochemically assessed Aβ accumulation by measuring the level of PBS insoluble Aβ40 and Aβ42 from TREM2 WT and TREM2 Het cortical tissue. As expected given the immunohistological data, female mice had significantly higher amounts of insoluble Aβ40 and Aβ42 than male mice. However, there was no genotype-dependent difference in the levels of insoluble Aβ40 or Aβ42 (Figure 2). Taken together, these data suggest that TREM2 hemizygosity has no effect on Aβ plaque burden during the early stages of Aβ deposition. [Figure: TREM2 heterozygosity does not affect Aβ plaque deposition in 3-month old APPPS1-21 mice. (A-D) Representative coronal brain sections from 3-month old from male TREM2 WT (A), male TREM2 Het (B), female TREM2 WT (C) and female TREM2 Het (D). Sections were immunostained with a biotinylated anti-Aβ antibody HJ3.4. (E) Quantification of the percentage of cortical area occupied by Aβ immunostaining. Two-way ANOVA analysis found a significant effect of gender (F1,39 = 13.63, p = 0.0007), but not genotype (F1,39 = 0.25, p = 0.62). (F) Quantification of the percentage of cortical area occupied by X-34 staining. Two-way ANOVA analysis found a significant effect of gender (F1,39 = 14.33, p = 0.0005), but not genotype (F1,39 = 0.08, p = 0.78; TREM2 WT (male, n = 12; female, n = 12) TREM2 Het (male, n = 9; female, n = 10)). Data are presented as mean ± SEM.] [Figure: TREM2 heterozygosity does not affect PBS-insoluble Aβ levels in 3-month old APPPS1-21 mice. (A) Mean concentrations of PBS-insoluble Aβ40 in cortical tissue from TREM2 WT (male, n = 13; female,